Cetuximab binds EGFR on target cells and its IgG1 Fc engages Fcγ receptors on NK cells to mediate ADCC (and can trigger complement-dependent cytotoxicity), leading to lysis of EGFR-positive cells; EGFR blockade mainly inhibits proliferation.